Ixekizumab

A4DAB148 | Immune-mediated / inflammatory disorders | Approved

Target IL17A

Isotype / Subclass G4 / IgG4

Company

Eli Lilly Oregon Health & Science University Torii Pharmaceutical

Clinical Status Approved

Format Whole mAb

Synonyms

LY-2439821 LY2439821 LY 2439821 Taltz

pH Formulation 5.3-6.1

IMGT PubChem (160704157) PubChem (187051842) PubChem (347911203) PubChem (377483925) PubChem (381126990) PubChem (461629170) PubChem (463561820) PubChem (472264651) PubChem (472409975) PubChem (481101723) PubChem (481155371) PubChem (498155235) Thera-SAbDab YAbS

Avg A4D Score

-0.6935

Score Range

-0.7 to -0.68

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB148_6nov_A_B	6nov	100%	-0.6849	6.5	4.0	-0.1857	-0.752
A4DAB148_6nov_C_D	6nov	100%	-0.7021	6.5	4.0	-0.3044	-0.7555

Ixekizumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2